Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC Clear all
Terminated Phase 2 Interventional

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AN-1792 also known as AIP-001
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
11
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 7, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

NCT00606476
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab (AAB-001)
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
29
States / cities
Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 (vanutide cridificar)
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

NCT01227564
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

NCT00574132
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
219
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 7, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00916617
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

NCT01193608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Results available

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 7, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00960531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 7, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT00937352
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
51 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
176
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 7, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Experimental Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • La Habra, California • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 10:42 AM EDT